Trial results

Feasibility assessments

  • Cassidy-Seyoum SA, Chheng K, Chanpheakdey P, Meershoek A, Hsiang MS, von Seidlein L, Adhikari B, Tripura R, Ley B, Price RN, Lek D, Engel N*, Thriemer K* (*shared last author). Perceptions of shorter radical cure P. vivax treatment regimens and their implementation: A qualitative study among stakeholders in Cambodia. Malar J. 2025 Sep 30;24(1):304. doi: 10.1186/s12936-025-05525-0.
  • Cassidy-Seyoum SA, Mwaura M, Chheng K, Kejela M, Korra KG, Wodaj T, Degaga TS, Hsiang MS, von Seidlein L, Tripura R, Adhikari B, Ley B, Lek D, Price RN, Engel N, Thriemer K. Co-design of a routine clinical review to improve the safety of high dose radical cure treatment for Plasmodium vivax malaria: findings from Cambodia and Ethiopia.  Malar J. 2025 May 28;24(1):171. doi: 10.1186/s12936-025-05425-3.
  • Cassidy-Seyoum SA, Chheng K, Chanpheakdey P, Meershoek A, Hsiang MS, von Seidlein L, Tripura R, Adhikari B, Ley B, Price RN, Lek D, Engel N, Thriemer K. Implementation of Glucose-6-Phosphate Dehydrogenase (G6PD) testing for Plasmodium vivax case management, a mixed method study from Cambodia. PLOS Glob Public Health. 2024 Jul 19;4(7):e0003476. doi: 10.1371/journal.pgph.0003476.
  • Cassidy-Seyoum S, Adhikari B, Chheng K, Chanpheakdey P, Meershoek A, Hsiang MS, von Seidlein L, Tripura R, Ley B, Price RN, Dysoley L, Thriemer K*, Engel N* (*shared last author). Acceptability and feasibility of Glucose-6-Phosphate Dehydrogenase (G6PD) testing using SD Biosensor by village malaria workers in Cambodia: a qualitative study. BMJ Glob Health. 2025 Jun 16;10(6):e019615. doi: 10.1136/bmjgh-2025-019615.

Stakeholder engagement

  • Qurashi B, Zaidi SE, Mushtaque M, Faisal A, Haroon Z, Agha B, Hammal N, Hameed A, Raza A, Ali U, Khan A, Jabbar FA, Adam ZR, Mehmood T, Price RN, Ghanchi N, Thriemer K*, Beg MA (*corresponding author). Effectiveness of tafenoquine and primaquine for radical cure of Plasmodium vivax: a meeting report from dissemination of results of the EFFORT trial to stakeholders in Pakistan. Malar J. 2025 Nov 11;24(1):393. doi: 10.1186/s12936-025-05636-8.
  • Dysoley L, Cassidy-Seyoum S, Adhikari B, Dahal A, Phoumen N, Srey S, Phalla T, Vonn P, Engrkruy B, Sovanarath O, Mengkea H, Rathana P, Makara I, Heng PK, Heng Y, Khlok H, Pong K, Moeng T, Vantha S, Soviet U, Ravuth R, Bunreth V, Vannak K, Sokhann M, Kimmen K, Dy K, Samol S, Lo K, Sokunthea N, Kry H, Kanha L, Naren L, Oum S, Sovann Y, Channavuth R, Bunmeng C, Hughes J, Brindle H, Hu Y, Peng S, Mardi P, Chanry I, Preap S, Heoy S, Sabawoon F, Sokha T, Ringwald P, Lynch CA, Price RN, Tripura R, von Seidlein L, Devine A, Thriemer K. Moving towards high-dose primaquine or single-dose tafenoquine for P. vivax treatment in Cambodia: A meeting report from dissemination of results of the EFFORT trial to stakeholders. Malar J. 2026 Jan 3;25(1):2. doi: 10.1186/s12936-025-05691-1.

Patient preferences

  • Bamboro SA, Jabbar FA, Bagita-Vangana M, Hasibuan N, Degaga TS, Ghanchi N, Beg AM, Tripura R, Pitaloka AP, Tego TT, Safitri W, Yulita, Cassidy-Seyoum SA, Mwaura M, Mnjala H, Lee G, Dysoley L, von Seidlein L, Price RN, Unger HW, Adjikari B, Thriemer, K. (2025). How do study participants want to be informed about study results: findings from a malaria trial in Cambodia, Ethiopia, Pakistan and Indonesia. Journal of Clinical and Translational Science, 1–29. doi:10.1017/cts.2025.56